Indoco Remedies · NSE: INDOCO · BSE: 532612
Q4 FY24 results · Jan–Mar 2024
Indoco Remedies reported revenue from operations of ₹449.64 crore (up 5.0% from Q4 FY23) and net profit of ₹22.03 crore (down 14.6% from Q4 FY23) for Q4 FY24 (Jan–Mar 2024), on a consolidated basis.
| Item | Q4 FY24 | Q4 FY23 | YoY | Q3 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 449.64 | 428.16 | +5.0% | 459.42 | −2.1% |
| Other income | 2.66 | 0.50 | +432.0% | 2.35 | +13.2% |
| Total income | 452.30 | 428.66 | +5.5% | 461.77 | −2.1% |
| Profit before tax | 32.98 | 38.93 | −15.3% | 22.63 | +45.7% |
| Net profit for the period | 22.03 | 25.81 | −14.6% | 15.56 | +41.6% |
| Attributable to shareholders of the company | 22.70 | 25.81 | −12.0% | 16.30 | +39.3% |
| EPS, basic (₹) | 2.39 | 2.80 | −14.6% | 1.69 | +41.4% |
| Net margin (%) | 4.9 | 6.0 | 3.4 |
| Item | Q4 FY24 | Q4 FY23 | YoY | Q3 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 445.49 | 427.46 | +4.2% | 449.05 | −0.8% |
| Other income | 4.05 | 0.49 | +726.5% | 2.93 | +38.2% |
| Total income | 449.54 | 427.95 | +5.0% | 451.98 | −0.5% |
| Profit before tax | 46.50 | 38.33 | +21.3% | 27.02 | +72.1% |
| Net profit for the period | 37.56 | 25.37 | +48.0% | 20.01 | +87.7% |
| EPS, basic (₹) | 4.08 | 2.75 | +48.4% | 2.17 | +88.0% |
| Net margin (%) | 8.4 | 5.9 | 4.5 |
Consolidated
- Filed with BSE
- 17 May 2024, 12:36 IST
- Board meeting
- 16 May 2024
- Period
- 01 Jan 2024 to 31 Mar 2024
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 17 May 2024, 12:36 IST
- Board meeting
- 16 May 2024
- Period
- 01 Jan 2024 to 31 Mar 2024
- Review status
- Audited
- Source
- XBRL filing on BSE